empty
 
 
ro
Search
Support
Instant account opening
Trading Platform
Deposit/Withdraw
Search
Pentru Începători Pentru Traderi Pentru Parteneri Luați o pauză Despre InstaSpot
ro
#AZN Reveniți la lista instrumentelor #BIIB

Convertor valutar

BeiGene Ltd.
189.79 USD
26 Nov 2024 19:19
Modificarea pretului (% chg)
$0
(0%)
Inchidere
Inchidere

Pretul de inchidere, ziua precedenta.
$189.02
Deschiderea
Deschiderea

Pretul de deschidere.
$191.2
Petul maxim
Petul maxim

Pretul maxim al ultimei zile de tranzactionare.
$189.79
Pretul minim
Pretul minim

Pretul minim al ultimei zile de tranzactionare.
$185.22
52-sapt. max.
52-sapt. max.

Pretul maxim din ultimele 52 spatamani.
$189.79
52-sapt. min.
52-sapt. min.

Pretul minim din ultimele 52 saptamani.
$183.79
Descărcați arhiva
Cumpărați
189.79
Vindeți
189.79
Deschideți graficul în ecran complet
Cumpărați
189.79
Vindeți
189.79
Descărcați arhiva
Deschideți graficul în ecran complet

BeiGene Ltd. About company

BeiGene Ltd. is a China-based biotechnology company founded in 2010 in Beijing. Nowadays, the company operates on an international scale with its branches established in the US, Australia, and Europe.

The company focuses on the development of drugs for cancer treatment. Since 2019, BeiGene Ltd. has been in partnership with Amgen Inc. and since, 2021 – with Novartis.

The market capitalization of BeiGene Ltd. is worth $17.7 billion. The company yielded a profit of $1.176 billion last year. In the first half of 2022, it earned $341.57 million. On the flip side, its net losses measured $1.413 billion in 2021 and $571.45 million in the first half of 2022.

BeiGene Ltd.’s stock and what influences its market quotes

BeiGene Ltd.’s stock has traded on the Nasdaq exchange under a BGNE ticker since 2016. Shortly after the listing, the shares traded at $24 apiece.

For the time being, the stock is trading in the range of $138 to $145. The stock has traded between the borders of $121.11 and $389.34 over the last 12 months.

The company does not pay dividends. All funds raised through investments are allocated for research and development.

What factors should investors keep an eye on when trading this asset:

  • BeiGene’s business belongs to a rapidly-developing sector. So, the company should have its finger on the pulse of science not to lag behind its competitors.
  • The major risk is that the company is sensitive to regulatory acts.
  • Washington slaps sanctions on Chinese companies now and then. In this context, they might be delisted from American exchanges.
  • The company ranks high. Hence, its stock is attractive to investors.

Nu puteti sa vorbiti acum?
Puneti intrebare in chat.